More than two million new cases of cancer will be diagnosed in the United States in 2024, according to the National Cancer Institute. Range Cancer Therapeutics ETF (Nasdaq: CNCR) is partnering with Cold Spring Harbor Laboratory (CSHL) to highlight CSHL’s pioneering role in advancing cancer research. Through the partnership, 23% of revenues generated by fees from CNCR will be donated to CSHL quarterly.
Bringing together the powers of philanthropy and investing, Range ETFs and CSHL announced this unique affiliation with a historic event at the Nasdaq stock market on November 14, 2024. The event featured a powerful visual display on the Nasdaq tower, and Range ETFs and CSHL leadership and guests gathered on the iconic Nasdaq podium to mark this momentous occasion.
“Cold Spring Harbor Laboratory is one of only seven national basic biological research cancer centers designated by the National Cancer Institute in Washington DC. Cancer research is fundamental to our discovery efforts,” said CSHL President and CEO Bruce Stillman. “The institution is investing heavily in the growth of our cancer program, specifically in multidisciplinary, collaborative ventures as part of our new brain-body physiology initiative.”
Range ETFs CNCR ETF focuses on companies dedicated to cancer research, treatment, and therapeutics, offering investors targeted exposure in this vital sector. It is purpose-built to provide exposure to a wide range of cancer therapeutic modalities.
“The contribution from Range will directly benefit the research efforts at CSHL, underscoring our commitment to advancing scientific innovation in oncology therapeutics,” said Range ETFs founder and CSHL Association Board Member, Tim Rotolo. “CNCR ETF provides exposure to nearly the entire lifecycle of drug development and distribution, and this new collaboration with CSHL provides an opportunity for investors to also see their money go toward the earliest stages of cancer breakthroughs.”
Stillman added that unique partnerships like this provide opportunities to engage with people who are already committed to scientific advancement and maximize efforts to support cancer research in unique ways.
Investing involves risk, including possible loss of principal. There is no guarantee the Fund will achieve its stated investment objectives. The Fund is non-diversified. Its concentration in an industry or sector can increase the impact of, and potential losses associated with, the risks from investing in those industries/sectors.
Exchange Traded Concepts, LLC serves as the investment advisor to the Fund. The Fund is distributed by Quasar Distributors, LLC. Quasar is not affiliated with Exchange Traded Concepts, LLC.
Written by: Lisa Cruz, Vice President, Communications | cruz@cshl.edu | 516-367-6846
About Range Fund Holdings, LLC
Range Fund Holdings, based in Cold Spring Harbor, NY, is the parent of Range ETFs (rangeetfs.com) a dedicated, life-cycle investment platform for exchange listed funds. Tim Rotolo is the Founder and CEO of Range Fund Holdings, LLC. He is also founder and CEO of Lloyd Harbor Capital Management, LLC (LHCM).